![](https://tracker.prod.prod.rnssubmit.com/track.live-rns/4474703_75d1671758db0ed18eba2dbba83793b2.png)
Spectra Systems Corporation
15 August, 2022
Spectra Systems Corporation ("Spectra")
New Central Bank Contract Amendment for Expanded Sensor Testing
Spectra Systems Corporation, a leader in machine-readable high speed banknote authentication, brand protection technologies and gaming security software, is pleased to announce that it has executed an amendment to a contract with a central bank customer (most recently announced on 15 June 2022) to support expanded testing of sensors prior to delivery. As a result, approximately $4mm of additional revenue is contracted in the period to 31 December 2024. A significant portion of the profits from this unexpected contract amendment will be used towards additional sales and marketing efforts for our machine-readable secure polymer substrate, FusionTM.
Dr. Nabil Lawandy, Chief Executive Officer, stated: "This new contract amendment will provide additional pre-production data to our customer prior to implementing our sensors in the field. This additional contract will further increase the development phase revenue from $10.8 million to $14.8 million, while maintaining the existing timeline for sensor manufacturing"
This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended ("MAR"). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
Enquiries:
Spectra Systems Corporation Dr. Nabil Lawandy, Chief Executive Officer
| Tel: +1 (0)401 274 4700
|
WH Ireland Limited (Nominated Adviser and Joint Broker) Chris Fielding (Head of Corporate Finance) Andrew de Andrade (Corporate Finance)
Allenby Capital Limited (Joint Broker) Nick Naylor/James Reeve (Corporate Finance) Amrit Nahal (Sales and Corporate Broking) | Tel: +44 (0)20 7220 1650
Tel: +44 (0)20 3328 5665
|
| |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.